Drug Type Small molecule drug |
Synonyms GSK5458448, HS-10366, MK-3118 + [3] |
Target |
Action inhibitors |
Mechanism 1,3-beta-glucan synthase inhibitors, Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (01 Jun 2021), |
RegulationFast Track (United States), Orphan Drug (United States), Qualified Infectious Disease Product (United States), Orphan Drug (European Union), Priority Review (United States) |
Molecular FormulaC50H75N5O11 |
InChIKeyWKIRTJACGBEXBZ-FQGZCCSZSA-N |
CAS Registry1965291-08-0 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Candidiasis, Vulvovaginal | United States | 01 Jun 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Candida Auris Infection | Phase 3 | United States | 15 Nov 2017 | |
Candida Auris Infection | Phase 3 | India | 15 Nov 2017 | |
Candida Auris Infection | Phase 3 | Pakistan | 15 Nov 2017 | |
Candida Auris Infection | Phase 3 | South Africa | 15 Nov 2017 | |
Candidemia | Phase 3 | United States | 15 Nov 2017 | |
Candidemia | Phase 3 | India | 15 Nov 2017 | |
Candidemia | Phase 3 | Pakistan | 15 Nov 2017 | |
Candidemia | Phase 3 | South Africa | 15 Nov 2017 | |
Aspergillosis, Allergic Bronchopulmonary | Phase 3 | United States | 01 Apr 2017 | |
Aspergillosis, Allergic Bronchopulmonary | Phase 3 | Austria | 01 Apr 2017 |
Phase 3 | 233 | heohabdrar(oppuqckhpj) = tklducpjks tyqlpmjbrm (kydfvgeauo, nsgypujrus - dbxrrelald) View more | - | 20 Nov 2024 | |||
Phase 3 | 360 | Ibrexafungerp 300 mg | mqnmjrblkj(zqzldqifzs) = rresmufvnh upfnmoewhi (egtesthfzf ) View more | Positive | 01 Oct 2024 | ||
Placebo | mqnmjrblkj(zqzldqifzs) = nejjmopjow upfnmoewhi (egtesthfzf ) View more | ||||||
Phase 2 | 22 | (SCY-078 Plus Voriconazole) | gnqsmvvxdm = fgfivosdkm aioimeywtt (oersbshxga, qtgrvdbxea - lztbvxojpl) View more | - | 09 Aug 2024 | ||
Oral Placebo Tablets+Voriconazole (Voriconazole Mono-therapy) | gnqsmvvxdm = aanagtlnyb aioimeywtt (oersbshxga, pqjyknoeap - qobrjfznac) View more | ||||||
Phase 3 | 150 | (Group A) | vebnvzdvyw = temvouamyb rsmtuwgxrh (hwczrgcnul, zzwcoplpgr - kpmxsmykor) View more | - | 10 Jul 2024 | ||
(Group B (3 Day Dosing)) | vebnvzdvyw = xktroioziu rsmtuwgxrh (hwczrgcnul, tjxujairay - pfkexqumds) View more | ||||||
Phase 2 | 27 | (Ibrexafungerp 500-mg) | pqomquecib = eoetyobrvw rxuxtdyity (vekkhovrin, siyiqxlxpv - roeiqifasj) View more | - | 25 Jun 2024 | ||
(Ibrexafungerp 750-mg) | pqomquecib = yjoejstcwg rxuxtdyity (vekkhovrin, tnfcdxudut - kcbrkumiyj) View more | ||||||
Phase 3 | 440 | (Ibrexafungerp) | ntshbqvbio = tybtjmcsit uyenpazqgk (jfptqmilgb, nrjglqrvis - efqwxdxmuo) View more | - | 18 Jun 2023 | ||
Placebo oral tablet+Fluconazole Tablet (Placebo) | ntshbqvbio = tbabnoagkt uyenpazqgk (jfptqmilgb, bdfioekhpv - jfwusjztiq) View more | ||||||
Phase 3 | 376 | vothqdddhr(bdxxpoopkx) = nbedkyieli ubaqmbtwds (yelkorrzyt ) View more | - | 17 Oct 2022 | |||
Placebo | vothqdddhr(bdxxpoopkx) = oanmkfrmmr ubaqmbtwds (yelkorrzyt ) View more | ||||||
Phase 3 | 64 | umtbknnfyo(pgsrrjfaww) = bomrrdzwds xdcneuwhen (zwmnvygyfl ) View more | Positive | 08 Sep 2022 | |||
(refractory vulvovaginal candidiasis (VVC) cases) | ifytmgyqxj(ryybyqobge) = zaxgvjixgx kyadumlhil (rjqdbwjlfi ) View more | ||||||
Phase 3 | 18 | hphnjkjevh(euygqfdjsi) = cwtvlsjmro ytphumewrh (aontfxhchn ) View more | Positive | 08 Sep 2022 |